Science

Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings

Khalid El Bairi/LinkedIn

Jun 8, 2025, 08:48

Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared an article on LinkedIn:

“This is our latest publication in the European Journal of Cancer in which we demonstrated that low-dose anti-PD-(L1) immune checkpoint inhibitors are also effective and may improve access, especially in resource-limited settings.

Find more here.”

Authors: Pablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, Ilves Sanna, Khalid El Bairi, Shah Zeb Khan, Amol Akhade, Teresa Amaral, Dario Trapani, Amol Patel, and Kevin J. Harrington.

You can read the full article on European Journal of Cancer.

More posts featuring Khalid El Bairi.

Amol Akhade Amol Patel anti-PD-L1 cancer Cancer Immunotherap Dario Trapani European Journal of Cancer Failah Mohamed fight against cancer Global fight against cancer ICIs Ilves Sanna Immune Checkpoint Inhibitors Kevin J. Harrington. Khalid El Bairi Low-Dose PD-(L)1 Inhibitor Nur Jihan Irwan Tan OncoDaily Oncology Pablo Jiménez-Labaig Shah Zeb Khan Teresa Amaral The Cancer Biomarkers Working Group

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders

Zongertinib Gets FDA Green Light for HER2+ NSCLC